Gemcitabine

製品コードS1714 別名：LY-188011, NSC 613327

Gemcitabine 化学構造

分子量(MW)：263.2

Gemcitabine, a nucleic acid synthesis inhibitor, is a very potent and specific deoxycytidine analogue, used as chemotherapy.

サイズ 価格(税別)  
JPY 21580.00
JPY 16102.00
お問い合わせ バルク問合せ

文献中Selleckの製品使用例(21)

カスタマーフィードバック(4)

  • RNA incorporating drugs induce SG assembly. HeLa cells were treated with the RNA incorporating agents 5-azacytidine (50 uM) and 6-thioguanine (10 uM), or the DNA incorporating agents trifluorothymidine (10 uM) and gemcitabine (100 nM) for 72 h. Subsequently, the cellular localization of the SG marker protein TIAR (green) and the P-body marker protein DCP1 (red) was analyzed. Nuclei were stained with Hoechst. Scale bars represent 20 um.

    Nucleic Acids Res 2014 42(10), 6436-47. Gemcitabine purchased from Selleck.

    Mice were administered either vehicle, gemcitabine (120 mg/kg [PaCa2]) or 20 mg/kg of BBI608 i.p. After killing, tumors were collected after 7 or 14 d of treatment, for Paca-2 and FaDu cells, respectively. Single-cell suspensions were obtained after animal killing and sterile removal of tumors. Live cells were then counted and used to measure their ability to form spheres when cultured in cancer stem cell media.

    Proc Natl Acad Sci USA, 2015, 112(6): 1839-44. Gemcitabine purchased from Selleck.

  • Immunofluorescent analysis of gemcitabine-induced γH2A.X and 53-BP1 focus formation. a, b Immunofluorescence staining of γH2A.X(green), 53-BP1 (red), and nuclei staining with DAPI (blue) in T24 (a) and T24r GEMCI20 (b) cells after the indicated treatments. Scale bar = 50 μm

    J Exp Clin Cancer Res, 2017, 36(1):1. Gemcitabine purchased from Selleck.

    Cells were seeded in 96 well paltes, and then treated with the indicated concentration of Gemcitabine for 48h. Cell survival was measured by a standarad MTT assay.

    Dr. Helen Sadik of Johns Hopkins University. Gemcitabine purchased from Selleck.

製品安全説明書

DNA/RNA Synthesis阻害剤の選択性比較

生物活性

製品説明 Gemcitabine, a nucleic acid synthesis inhibitor, is a very potent and specific deoxycytidine analogue, used as chemotherapy.
体外試験

Gemcitabine results in 50% inhibition of growth in the CCRF-CEM human leukemia cell culture assay with IC50 of 1 ng/ml. Gemcitabine combined with deoxycytidine provides about a 1000-fold decrease in biological activity. [1] Gemcitabine combined with C225 results in additive cytotoxic effects that increased with increasing gemcitabine concentrations in human pancreatic carcinoma L3.6pl cells. [2] Gemcitabine combined with Cisplatin results in synergistic effect in wild-type A2780 and cisplatin-resistant ADDP cells. [3]
細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MV-4-11 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTtTWM2OD1yLkCwNFQ2QCCwTR?= NWK2bY85W0GQR1XS
ES4 M1fy[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTBwMECwOlU{KG6P MlmzV2FPT0WU
ACHN NXjRe2MzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\0XmlEPTB;MD6wNFA5QDdibl2= Mnm4V2FPT0WU
KYSE-510 NXPzUGRFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTBwMECwPVc2KG6P MYnTRW5ITVJ?
EW-7 NGiwZ4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mkf1TWM2OD1yLkCwNlU5KG6P NFnYbnNUSU6JRWK=
BFTC-905 M3fJ[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfSTWM2OD1yLkCwOVE2KG6P NYnWbZpHW0GQR1XS
KE-37 NX3MXJczT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\0cYtUUUN3ME2wMlAxPTZzIH7N MXvTRW5ITVJ?
SBC-5 MmS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHaTYlKSzVyPUCuNFA2PyCwTR?= NVPQV3F1W0GQR1XS
NKM-1 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWrwSFFnUUN3ME2wMlAxPzB7IH7N MlHIV2FPT0WU
RH-1 MkfJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlm1TWM2OD1yLkCwO|E5KG6P MULTRW5ITVJ?
ALL-PO NFe0XHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLvTWM2OD1yLkCwPFMhdk1? MojaV2FPT0WU
QIMR-WIL NHOwPHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\PdYtKSzVyPUCuNFA5QTRibl2= NVvUeoJrW0GQR1XS
A375 NF;NRWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3fsXGlEPTB;MD6wNFk6PSCwTR?= M1v4O3NCVkeHUh?=
SIG-M5 MmXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTBwMEGwOEBvVQ>? MkjQV2FPT0WU
KGN M1TTe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTBwMEGwPEBvVQ>? NYnHbphjW0GQR1XS
EW-13 NEGxc2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\tOYNKSzVyPUCuNFEyOiCwTR?= MnjSV2FPT0WU
NCI-SNU-1 NX34UZhRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvq[lFKSzVyPUCuNFE3KG6P MmTWV2FPT0WU
PSN1 NUD4[VhJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGe1b4ZKSzVyPUCuNFE3PSCwTR?= NG\OZ4pUSU6JRWK=
HUTU-80 NIfofmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;xRZJKSzVyPUCuNFE3PiCwTR?= M1z1SnNCVkeHUh?=
EW-16 M2ToXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTBwMEKzJI5O M1jkUXNCVkeHUh?=
786-0 NYi0OWlDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWqxR45NUUN3ME2wMlAzOyCwTR?= M3vCfHNCVkeHUh?=
ES1 M1TIXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2ruc2lEPTB;MD6wNlY5KG6P NFfHUolUSU6JRWK=
RKO MmXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DtNmlEPTB;MD6wNlc6KG6P MYPTRW5ITVJ?
ESS-1 NFi3OJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFK1[o9KSzVyPUCuNFI5PiCwTR?= NW\XSHFIW0GQR1XS
SK-UT-1 M1fsTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXmTWM2OD1yLkCyPVchdk1? M33rOnNCVkeHUh?=
LB2241-RCC M1z1Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXFdFIzUUN3ME2wMlA{OThibl2= MkjBV2FPT0WU
CHL-1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfPV417UUN3ME2wMlA{OjRibl2= NXq1W5FoW0GQR1XS
SW1783 Ml7GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTBwMEOzOkBvVQ>? MUjTRW5ITVJ?
MEL-JUSO Ml72S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXqTWM2OD1yLkCzPVEhdk1? MUTTRW5ITVJ?
HT-29 MoTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLG[XlKSzVyPUCuNFQyOyCwTR?= NGTYWodUSU6JRWK=
SNG-M M2HqOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;yPI9KSzVyPUCuNFQzPSCwTR?= NEXFOJdUSU6JRWK=
TE-15 NYHNWXZzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkKyTWM2OD1yLkC0OlQhdk1? MXrTRW5ITVJ?
HOS M4Cz[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHNRoNsUUN3ME2wMlA1QCCwTR?= MXXTRW5ITVJ?
BB65-RCC MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonSTWM2OD1yLkC1NVIhdk1? MXLTRW5ITVJ?
HCE-4 NVPFUJRyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTBwMEWyPEBvVQ>? M3nkVXNCVkeHUh?=
MHH-ES-1 M{\Wdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvrclRKSzVyPUCuNFU{OSCwTR?= MlzXV2FPT0WU
RPMI-7951 NYnSTWlLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LTRWlEPTB;MD6wOVQyKG6P NYXpN|JwW0GQR1XS
IST-SL2 NX[wfIc4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTBwMEW4OEBvVQ>? Mn\FV2FPT0WU
CMK NH7Rb|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\CbIxKSzVyPUCuNFU5PiCwTR?= M2HvR3NCVkeHUh?=
GR-ST MlvUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkH4TWM2OD1yLkC1PVUhdk1? M2fuNnNCVkeHUh?=
NALM-6 M1;qNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3xTGM5UUN3ME2wMlA3OjJibl2= M3X0eXNCVkeHUh?=
RPMI-6666 NEDlVZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{mwSmlEPTB;MD6wOlUzKG6P NX;2NYNoW0GQR1XS
LC-2-ad NVPVbYpiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\qW4FCUUN3ME2wMlA3PTNibl2= NH3k[G9USU6JRWK=
ARH-77 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvSZlBQUUN3ME2wMlA4OTFibl2= NU\DSIF4W0GQR1XS
IST-MEL1 NUDxRlc5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmGzTWM2OD1yLkC3NlYhdk1? NYrxN4xDW0GQR1XS
SW1710 M4nIOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTBwMEe1NUBvVQ>? Mon6V2FPT0WU
DEL MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTBwMEi4O{BvVQ>? MkjFV2FPT0WU
AGS MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTBwMEmwNkBvVQ>? NEPwOVRUSU6JRWK=
NCI-H2122 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXMWVVGUUN3ME2wMlA6PDZibl2= NUC0bIR[W0GQR1XS
HSC-4 NGT6dIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTBwMUCyJI5O MXjTRW5ITVJ?
AM-38 NETRR|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnCTWM2OD1yLkGyNUBvVQ>? MlvmV2FPT0WU
769-P MoW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLPd3pLUUN3ME2wMlEzOyCwTR?= MkjwV2FPT0WU
RT-112 M4K4emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTBwMUK3JI5O MnLEV2FPT0WU
MCF7 NEH6cllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHe2T2xKSzVyPUCuNVM3KG6P NGG1UY9USU6JRWK=
IGROV-1 Mn\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\aZ3ZqUUN3ME2wMlE1PSCwTR?= MUXTRW5ITVJ?
OCI-AML2 NGG2dJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTZTWM2OD1yLkG0O{BvVQ>? NGjlO5VUSU6JRWK=
NCI-H1299 M2DGUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDpTWM2OD1yLkG1O{BvVQ>? MlzpV2FPT0WU
A431 NUj4bHE6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTBwMUizJI5O NH;2V2pUSU6JRWK=
SW982 M4q4Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrWXFRUUUN3ME2wMlIyOyCwTR?= MYfTRW5ITVJ?
BB30-HNC NV\xflZyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHJTWM2OD1yLkKzNUBvVQ>? NIfmUFBUSU6JRWK=
ACN NV\RUnNiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XoNmlEPTB;MD6yOFQhdk1? M1XoZ3NCVkeHUh?=
647-V NFjNeFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlP2TWM2OD1yLkK0PEBvVQ>? NULtT3NoW0GQR1XS
SK-PN-DW M3Xzd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\RcGlEPTB;MD6yOlYhdk1? NYG4W3VzW0GQR1XS
LCLC-97TM1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3TQOmlEPTB;MD6yOlchdk1? NIrQVIJUSU6JRWK=
LB1047-RCC MorTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVG5bW1yUUN3ME2wMlI3QSCwTR?= MUPTRW5ITVJ?
A2780 MkLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTBwMkegcm0> M4rnd3NCVkeHUh?=
C-33-A NXzzZmRoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\LTWM2OD1yLkK3N{BvVQ>? M{TnOHNCVkeHUh?=
NCI-H2228 NEDrZ21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;SXJBKSzVyPUCuN|E1KG6P NFH3SllUSU6JRWK=
TE-5 M4PNfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXJTWM2OD1yLkOxOkBvVQ>? NYDGV3A1W0GQR1XS
HC-1 NImydnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXL5dFhDUUN3ME2wMlMzPyCwTR?= MmqyV2FPT0WU
SK-MES-1 NHnUbpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVv2SotSUUN3ME2wMlMzQCCwTR?= MoLUV2FPT0WU
NCI-H1355 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jQNWlEPTB;MD6zPFEhdk1? NGT6Z2tUSU6JRWK=
YKG-1 M3v2PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{HCSGlEPTB;MD60NVkhdk1? NX\V[lFQW0GQR1XS
RS4-11 MnT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDVOWRKSzVyPUCuOFM{KG6P M3XNPHNCVkeHUh?=
Daoy NU\rfW1MT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3GxOWlEPTB;MD60OVYhdk1? MVTTRW5ITVJ?
A3-KAW MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NImwNnpKSzVyPUCuOVUyKG6P NHnRNXJUSU6JRWK=
SK-MEL-30 NEW3e5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NECwfppKSzVyPUCuOVU1KG6P NHnwZVlUSU6JRWK=
U031 NVLzT3pET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGi2Nm5KSzVyPUCuOVY2KG6P NITwW2hUSU6JRWK=
SK-LMS-1 NXH1WmxKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7NTWM2OD1yLkW3PEBvVQ>? MY\TRW5ITVJ?
ES6 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHr1UJRKSzVyPUCuOVg3KG6P NFLIeGxUSU6JRWK=
EoL-1-cell M3ftOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vpbmlEPTB;MD62NVYhdk1? NH3Mc2dUSU6JRWK=
NCI-H2009 MmfYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTBwNkG5JI5O MUjTRW5ITVJ?
A4-Fuk M3eyUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTBwNkK2JI5O NETNfWhUSU6JRWK=
KYSE-270 M37TVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\yUJNKSzVyPUCuOlM1KG6P NYDkT3hPW0GQR1XS
SK-LU-1 M1jZXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{LDUGlEPTB;MD62OVUhdk1? MWrTRW5ITVJ?
SW872 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTBwN{[1JI5O NVzpNmhKW0GQR1XS
ES8 NYjMVmxNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTBwN{igcm0> NXPFTo93W0GQR1XS
G-402 NFu4cpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2TyN2lEPTB;MD63PFQhdk1? MoPLV2FPT0WU
ATN-1 MoDtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1r5RWlEPTB;MD64NFchdk1? NWO1XldqW0GQR1XS
DoTc2-4510 M2r2UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXHeJNjUUN3ME2wMlkxOSCwTR?= NYO5ZVUxW0GQR1XS
MES-SA NUnae2xyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTBwOUC1JI5O NFrUUFZUSU6JRWK=
SF268 NYnIWXIxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTBwOUK3JI5O M1vpcXNCVkeHUh?=
SF539 NUC1R3VwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;0[49KSzVyPUGuNFIhdk1? M1zNcXNCVkeHUh?=
NB69 NFvaUpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTFwMEWgcm0> MYrTRW5ITVJ?
8505C MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PJemlEPTB;MT6wOkBvVQ>? NX:4R4l3W0GQR1XS
CAL-12T M1vZZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTFwMEigcm0> NIHZb|lUSU6JRWK=
BHY MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGXHNJJKSzVyPUGuNVQhdk1? M4\DWHNCVkeHUh?=
LB647-SCLC M3PnSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3f3cWlEPTB;MT6xPEBvVQ>? M2nMN3NCVkeHUh?=
CAL-62 NEPKUnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIP5e2dKSzVyPUGuNlIhdk1? MYfTRW5ITVJ?
MEG-01 MmfUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PTfmlEPTB;MT6yO{BvVQ>? MnzaV2FPT0WU
MG-63 MoXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX3YSppOUUN3ME2xMlM{KG6P NYq5W4Q3W0GQR1XS
SW620 NVW2PYZuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTFwM{Wgcm0> NEjEV3dUSU6JRWK=
A388 NXXJTmNHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHwOm9uUUN3ME2xMlM3KG6P MUHTRW5ITVJ?
BCPAP NFjCSY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmr6TWM2OD1zLkS1JI5O NETQOYZUSU6JRWK=
P30-OHK NEHRfWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknHTWM2OD1zLkS2JI5O M4X0T3NCVkeHUh?=
Ca9-22 Mn7WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvRcZd{UUN3ME2xMlU1KG6P M{\HZXNCVkeHUh?=
VMRC-RCZ NFu0fGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnv0TWM2OD1zLkW0JI5O NEmyPJBUSU6JRWK=
LOXIMVI MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\YfmlEPTB;MT62JI5O MmDyV2FPT0WU
L-540 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7IeWRQUUN3ME2xMlYhdk1? MkLGV2FPT0WU
NTERA-S-cl-D1 NGDFO5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTFwNkSgcm0> NXriPHh6W0GQR1XS
MFH-ino NYjHWYV5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTFwNk[gcm0> M3i0SHNCVkeHUh?=
Calu-6 NFzN[mtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTFwN{Ogcm0> MV7TRW5ITVJ?
HEL Ml;4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1L1XGlEPTB;MT63PUBvVQ>? M3\PVnNCVkeHUh?=
CAL-33 M2PTe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTFwOEmgcm0> M3fqc3NCVkeHUh?=
HSC-3 M4TWeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmD2TWM2OD1zLkmxJI5O NXThT3RJW0GQR1XS
KU812 M4PTUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;MTWM2OD1zLkmxJI5O NGHwWHlUSU6JRWK=
EB2 NFHiPZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\yTWM2OD1{LkCxJI5O NYr5[JFuW0GQR1XS
SR M1;4PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHlOm9KSzVyPUKuNVIhdk1? NGPu[ldUSU6JRWK=
NCI-H2087 NIG2S5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PHN2lEPTB;Mj6xOEBvVQ>? NXP1bIhsW0GQR1XS
H4 M{TlcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnmcIxKSzVyPUKuNVghdk1? MofBV2FPT0WU
EW-1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3r6T2lEPTB;Mj6yNkBvVQ>? MV\TRW5ITVJ?
MC-IXC NV\TZoNiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7WXm9KSzVyPUKuNlYhdk1? M4PQNnNCVkeHUh?=
NCI-H727 NFLpZlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjydGJqUUN3ME2yMlUyKG6P MlviV2FPT0WU
MRK-nu-1 M4\1e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTJwNUegcm0> MUjTRW5ITVJ?
COLO-668 M4HMfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHyTWM2OD1{Lk[2JI5O M3XlW3NCVkeHUh?=
CGTH-W-1 NFrYNmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTJwN{Kgcm0> NWXUWZJwW0GQR1XS
CHP-212 NHnFUHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTJwN{Wgcm0> NGrzUolUSU6JRWK=
GI-1 M2\X[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnCXJFKSzVyPUKuO|Yhdk1? NG\5XW5USU6JRWK=
HCC1806 MoPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HSbGlEPTB;Mj65NUBvVQ>? NFL3Z2hUSU6JRWK=
HLE MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTNibl2= MWDTRW5ITVJ?
HSC-2 NXSzclRET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPjN2pKSzVyPUOuNFMhdk1? MYHTRW5ITVJ?
DMS-273 M2XrWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEn1VYxKSzVyPUOuNFchdk1? NG\teWtUSU6JRWK=
DU-4475 MmPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTNwMUSgcm0> NEm4TZNUSU6JRWK=
LXF-289 NEHxZnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTNwM{Ggcm0> MUPTRW5ITVJ?
PANC-03-27 NHrlOpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTDTWM2OD1|LkWxJI5O MVLTRW5ITVJ?
GAMG MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTNwN{Sgcm0> NXHveJlyW0GQR1XS
NCI-H522 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{[ze2lEPTB;ND6zOEBvVQ>? MXjTRW5ITVJ?
SW626 MmnYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGntfW5KSzVyPUSuOFYhdk1? NGXDWW9USU6JRWK=
HT-144 NXHkNlJOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLQS25KSzVyPUSuPVIhdk1? NWnP[FlUW0GQR1XS
MEL-HO NWrZcY9MT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnfkTWM2OD13LkG2JI5O MU\TRW5ITVJ?
BE-13 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jMOWlEPTB;NT6yNUBvVQ>? MnfBV2FPT0WU
VA-ES-BJ NHeybo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvHTGNKSzVyPUWuNlYhdk1? NXG5TVlyW0GQR1XS
NCI-H441 MkHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHrTWM2OD13Lk[gcm0> MoThV2FPT0WU
KP-4 NVHRTpQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{L1dmlEPTB;NT62NUBvVQ>? M2q5dXNCVkeHUh?=
LoVo MnflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn7kTWM2OD13LkexJI5O MofGV2FPT0WU
HT-1080 MnjqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHnZnhKSzVyPUWuPFMhdk1? NWWwOI5jW0GQR1XS
GB-1 NF61[JZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnGxTWM2OD13Lki0JI5O NV7zS2RqW0GQR1XS
IA-LM NVTjU5ZvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTVwOUGgcm0> NG\MTldUSU6JRWK=
8-MG-BA MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVS4VXBzUUN3ME21Mlk{KG6P MVrTRW5ITVJ?
SK-HEP-1 M4PwbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPFNXl2UUN3ME22MlE1KG6P MVTTRW5ITVJ?
697 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\GTWM2OD14LkK1JI5O MVnTRW5ITVJ?
KYSE-450 NIj6d4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHj5elBKSzVyPU[uN|Ihdk1? NEXKT|lUSU6JRWK=
HCC2998 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrxWndKSzVyPU[uN|Qhdk1? Mnz1V2FPT0WU
HD-MY-Z NEXZXnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTZwNkigcm0> MWnTRW5ITVJ?
OS-RC-2 NVfCeW51T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1L3VmlEPTB;Nj62PEBvVQ>? M1LqT3NCVkeHUh?=
SF126 NFXvZ5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTdwMEWgcm0> MXXTRW5ITVJ?
Ca-Ski M1fGWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELYOIlKSzVyPUeuNFkhdk1? M4rDUHNCVkeHUh?=
NCI-H358 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\mZ2lEPTB;Nz6xOkBvVQ>? M1f0TXNCVkeHUh?=
J82 NHXaPVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTdwNEGgcm0> NHjRTlRUSU6JRWK=
NCI-H2342 M2TIN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTdwNkOgcm0> NHX2NnNUSU6JRWK=
OVCAR-8 NXq5Wo9ET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUC4OphFUUN3ME23Mlkhdk1? Mof2V2FPT0WU
TE-8 NHzJfVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjYR49KSzVyPUigcm0> NVHBWZU3W0GQR1XS
ETK-1 M{XUWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4G0cmlEPTB;OD6wPEBvVQ>? NEDzVpJUSU6JRWK=
HAL-01 M3nuO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vWNGlEPTB;OD6yJI5O M3PxUnNCVkeHUh?=
KYSE-150 NUfSTZhkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorrTWM2OD16LkS3JI5O MkfpV2FPT0WU
NCI-H810 M2fMO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jqZ2lEPTB;OD61OkBvVQ>? M4\YZXNCVkeHUh?=
ONS-76 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTKTWM2OD16Lk[4JI5O NUfC[5hmW0GQR1XS
NMC-G1 NXjkO3B7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XKV2lEPTB;OD63OkBvVQ>? NFjFZVZUSU6JRWK=
C3A M17uS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDNdIRKSzVyPUiuPFQhdk1? NYfaPVU2W0GQR1XS
PA-1 M2rH[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRThwOUmgcm0> Ml64V2FPT0WU
SH-4 NUnhWm1UT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTlwMEKgcm0> MY\TRW5ITVJ?
EFO-27 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPPSVJKSzVyPUmuNFUhdk1? MlHWV2FPT0WU
CAPAN-1 Mm\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIC2WVVKSzVyPUmuNlMhdk1? NUPYSlJ5W0GQR1XS
DU-145 NED2cZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\oOpdDUUN3ME25MlI6KG6P MYnTRW5ITVJ?
A101D NEWwbpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HtOWlEPTB;OT6zO{BvVQ>? Mny4V2FPT0WU
ST486 MkHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvr[mZlUUN3ME25MlQyKG6P MoHwV2FPT0WU
NCI-H1437 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEW1cIZKSzVyPUmuOFIhdk1? M4H3WHNCVkeHUh?=
HGC-27 M2L1VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTlwNjDuUS=> NUPCc3E3W0GQR1XS
8305C NIjwclFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTlwNkSgcm0> MlG0V2FPT0WU
OCUB-M MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPpd5hKSzVyPUGwMlA{KG6P M4D0bnNCVkeHUh?=
COLO-679 NE\zPFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTFyLkC3JI5O NY\XcnFVW0GQR1XS
Detroit562 NFLqcY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXITo1KSzVyPUGwMlQzKG6P MXPTRW5ITVJ?
A204 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTaTWM2OD1zMT6xOkBvVQ>? M1XreHNCVkeHUh?=
NCI-H1734 NYjnW49mT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\2d2lEPTB;MUGuNlkhdk1? MXnTRW5ITVJ?
MC-CAR Mkj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfYOHRiUUN3ME2xNU42QCCwTR?= NUPTSHVWW0GQR1XS
NCI-H2170 M4W4cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\mV2lEPTB;MUGuPVchdk1? NES0fo9USU6JRWK=
NCI-SNU-5 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4Hkb2lEPTB;MUKuNVMhdk1? M3jTRnNCVkeHUh?=
HCE-T MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPSWYo2UUN3ME2xNk41OiCwTR?= MmXHV2FPT0WU
KYSE-180 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzDcpVDUUN3ME2xNk45OSCwTR?= NUjVelhGW0GQR1XS
C8166 NGHiZ3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDjW49KSzVyPUGzMlA5KG6P NHOxZmJUSU6JRWK=
NCI-H460 NInqdINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjJTWM2OD1zMz61OEBvVQ>? M2PCVHNCVkeHUh?=
SNU-449 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkH3TWM2OD1zMz63O{BvVQ>? MlLiV2FPT0WU
MDA-MB-468 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHm0SnlKSzVyPUG0MlEzKG6P NHHxcZFUSU6JRWK=
COR-L23 M130Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDndVBKSzVyPUG0MlE{KG6P NFf4UZJUSU6JRWK=
CTV-1 M4C0cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTF2LkG0JI5O M{XzS3NCVkeHUh?=
BL-41 Mof1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFj4UIhKSzVyPUG0MlM4KG6P NEfiRoJUSU6JRWK=
IGR-1 M2jMPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPkVoFKSzVyPUG0MlQzKG6P Ml7jV2FPT0WU
TK10 MlvvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\I[GlEPTB;MUSuOFkhdk1? MYHTRW5ITVJ?
REH MkjZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn:zTWM2OD1zND61NUBvVQ>? MWfTRW5ITVJ?
LU-139 NWTsXnBzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PNU2lEPTB;MUSuOVkhdk1? M3ywTnNCVkeHUh?=
KP-N-YS MlHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTF2Lkm3JI5O NVraT3gyW0GQR1XS
PANC-10-05 M4ewR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3nhOGlEPTB;MUWuN|ghdk1? NXzZVJRmW0GQR1XS
HL-60 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPIe2FlUUN3ME2xOU43QSCwTR?= NUDrWJZ4W0GQR1XS
T84 NUW0W3lET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjrcYYxUUN3ME2xOU46PiCwTR?= NXziOWRJW0GQR1XS
RPMI-8226 NUTibJVzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTF4LkCyJI5O NIHkU49USU6JRWK=
UM-UC-3 MofZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzldIhpUUN3ME2xOk4yPiCwTR?= NUHpXpFPW0GQR1XS
TE-10 M4TaXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\YT|lTUUN3ME2xOk4zOSCwTR?= Ml;4V2FPT0WU
CAL-148 NXfyUJI5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGmzcVBKSzVyPUG3MlI{KG6P NV7QVYhEW0GQR1XS
BV-173 MmPRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTF5LkK3JI5O M2rGbHNCVkeHUh?=
Calu-3 M1ryfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7iVZpKSzVyPUG3MlI6KG6P NYe1SVI1W0GQR1XS
RPMI-2650 M{\0WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTF5LkW5JI5O MUjTRW5ITVJ?
MKN45 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXaTWM2OD1zNz63N{BvVQ>? MoDHV2FPT0WU
NUGC-3 NX\mO4VJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWq3TpRXUUN3ME2xPE4{PCCwTR?= MlOwV2FPT0WU
NCI-H520 NX7nTGtPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17ZVmlEPTB;MUiuO|chdk1? M13ucHNCVkeHUh?=
CCRF-CEM Mk\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTF6Lki1JI5O NEHhb49USU6JRWK=
NCI-H2405 MorMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrUPZJRUUN3ME2xPU4yKG6P NXzkS2FpW0GQR1XS
ES7 NEPnSlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTF7Lke2JI5O NWH1eYU{W0GQR1XS
BPH-1 M3TZPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTJyLkK4JI5O Mnf4V2FPT0WU
SAS MlXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXX0RXFbUUN3ME2yNE42KG6P MX3TRW5ITVJ?
HuCCT1 NV7mN2N5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\mWIV6UUN3ME2yNE42QCCwTR?= Mm\VV2FPT0WU
LOUCY NEW1SlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;qVmlEPTB;MkCuOlYhdk1? M3TmXXNCVkeHUh?=
NCI-H292 MoPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDnTWM2OD1{MD63PUBvVQ>? MkLFV2FPT0WU
G-361 NHTMbWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrkNW12UUN3ME2yNU4xPyCwTR?= NGnafHlUSU6JRWK=
M059J NEHZe2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrsfWtKSzVyPUKxMlA5KG6P MmfZV2FPT0WU
NCI-H1651 M3TleWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\S[WlEPTB;MkGuNVEhdk1? NUP4fndKW0GQR1XS
KALS-1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jEWGlEPTB;MkGuN|khdk1? NXrMZZdxW0GQR1XS
DJM-1 NInYeIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{SxV2lEPTB;MkGuOVkhdk1? Ml3JV2FPT0WU
AU565 MkDXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXHeVJKSzVyPUKxMlg{KG6P NGX5WnpUSU6JRWK=
HCC38 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjDUFlKSzVyPUKxMlk2KG6P MnnGV2FPT0WU
U251 M1vm[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWf6bIJzUUN3ME2yNk4zPyCwTR?= NHrU[GtUSU6JRWK=
ABC-1 NYLKZY57T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHifYR{UUN3ME2yNk43PSCwTR?= MYjTRW5ITVJ?
SK-NEP-1 M3HxbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHiTWM2OD1{Mj65N{BvVQ>? MYnTRW5ITVJ?
CESS NX;SZ5R{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLlTWM2OD1{Mz6xPUBvVQ>? NFy0OWZUSU6JRWK=
MIA-PaCa-2 MorYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjwUlMyUUN3ME2yN{4{PiCwTR?= NYG2UoREW0GQR1XS
SUP-T1 M4DRNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHS0RXBKSzVyPUKzMlQ4KG6P NITsfYJUSU6JRWK=
L-428 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfPe4JKSzVyPUKzMlYzKG6P M1vEc3NCVkeHUh?=
SW954 M3ezPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPRW3RKSzVyPUKzMlY5KG6P MVXTRW5ITVJ?
HO-1-N-1 NUnMSI1FT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2nROmlEPTB;MkOuO|chdk1? MnHPV2FPT0WU
CHP-126 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fLbGlEPTB;MkSuNVQhdk1? NVHYfWdOW0GQR1XS
HMV-II MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHj0No5KSzVyPUK0MlM1KG6P M2XpSnNCVkeHUh?=
NB10 M{Dq[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;HUGlEPTB;MkSuN|chdk1? MmH0V2FPT0WU
A172 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTJ2LkexJI5O NGrwcoNUSU6JRWK=
MONO-MAC-6 MoPZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPPV5NGUUN3ME2yOE45PCCwTR?= NH;sWmJUSU6JRWK=
NCI-H1650 MmLCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mne5TWM2OD1{NT60JI5O MkjMV2FPT0WU
NH-12 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTJ3LkWgcm0> NX\lVG1xW0GQR1XS
ML-2 NV;5dVhNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn24TWM2OD1{NT63OEBvVQ>? NXPk[GZKW0GQR1XS
MZ2-MEL NYLibmZHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDhPI01UUN3ME2yOk4zOiCwTR?= NYmydldwW0GQR1XS
COLO-684 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HidmlEPTB;Mk[uOFEhdk1? MYDTRW5ITVJ?
HuP-T4 NYXNNYl1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFP0eoZKSzVyPUK3MlMhdk1? MmHIV2FPT0WU
SW837 NVryemt2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLFTWM2OD1{Nz62NkBvVQ>? NYDYcJh3W0GQR1XS
MDA-MB-231 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLXUlRuUUN3ME2yO{44QCCwTR?= NEDRdlJUSU6JRWK=
KYSE-140 M4Xhdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHpXnRVUUN3ME2yO{46OSCwTR?= NInObYNUSU6JRWK=
NOMO-1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIP0N5dKSzVyPUK4MlY5KG6P M17vUHNCVkeHUh?=
GP5d MofiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnBWFVKSzVyPUK4MlczKG6P NUf2bZczW0GQR1XS
COR-L105 NFn4c4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTrO5pzUUN3ME2yPU41OiCwTR?= MYjTRW5ITVJ?
LS-411N MnvkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTJ7Lki4JI5O NWrJV|M3W0GQR1XS
NY Mn3FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnmd3hkUUN3ME2zNE4yQCCwTR?= M{PRNXNCVkeHUh?=
NCI-H2030 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\T[pk2UUN3ME2zNE41PSCwTR?= MUDTRW5ITVJ?
CCF-STTG1 M{HKcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTNzLkSyJI5O NXu0UWhGW0GQR1XS
NCI-H1703 M33HdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTNzLke4JI5O NUDXXVVmW0GQR1XS
TUR M4HYTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\pfIlKSzVyPUOyMlA{KG6P MoPaV2FPT0WU
NOS-1 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rrdmlEPTB;M{KuOFQhdk1? NFT0WotUSU6JRWK=
A2058 NVvYUpI1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXqyOlBYUUN3ME2zNk45OyCwTR?= NE\jdGxUSU6JRWK=
LCLC-103H NHLq[ZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH63eVdKSzVyPUOzMlI2KG6P M3u0VXNCVkeHUh?=
NCI-H510A M3jVdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;qPGlEPTB;M{OuNlchdk1? M{jMNXNCVkeHUh?=
BC-1 MnKxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2[4bmlEPTB;M{OuO|chdk1? NXPnd293W0GQR1XS
SK-CO-1 M1vhdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnG5TWM2OD1|ND6wNUBvVQ>? NVHGS25LW0GQR1XS
A673 NGLleHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{C2VGlEPTB;M{SuNVchdk1? NVvhU|JYW0GQR1XS
VM-CUB-1 NGG0[ZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGry[YNKSzVyPUO0MlY6KG6P MVvTRW5ITVJ?
HH M4fmWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{jqTWlEPTB;M{WuNFYhdk1? MXTTRW5ITVJ?
CAL-27 NX3lWWdZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LQWGlEPTB;M{WuNVYhdk1? NH3SVJJUSU6JRWK=
NEC8 NUDrT|BtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\IdmlEPTB;M{WuN|chdk1? NEG0XY9USU6JRWK=
BxPC-3 NFLNTIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17FeGlEPTB;M{[uPVEhdk1? M2HjSXNCVkeHUh?=
SNB75 NUHQOXZpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnpWGpyUUN3ME2zO{4zPCCwTR?= MUXTRW5ITVJ?
NB13 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTN6LkKzJI5O NVyxS3o4W0GQR1XS
SK-OV-3 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{G4XmlEPTB;M{iuO|Qhdk1? MYDTRW5ITVJ?
ME-180 NXPWU|M4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHSTWM2OD1|OD64JI5O MlnGV2FPT0WU
JiyoyeP-2003 NGnBO|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo[xTWM2OD1|OT6zPEBvVQ>? MlnuV2FPT0WU
LU-134-A M4\wZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTRyLkCyJI5O MmW4V2FPT0WU
LS-123 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\oTWM2OD12MD6yPEBvVQ>? NIr2e|lUSU6JRWK=
COLO-800 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGH1dJRKSzVyPUSwMlU3KG6P NGHhXJFUSU6JRWK=
LB831-BLC M4\JXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTRzLki1JI5O MWjTRW5ITVJ?
NCI-H747 NUT3R45pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF3aO49KSzVyPUSyMlI5KG6P M37aT3NCVkeHUh?=
MZ7-mel MnTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1npcGlEPTB;NEKuOlYhdk1? MkTWV2FPT0WU
GT3TKB NYH5UFVGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTrZ2NKSzVyPUSyMlczKG6P NEjMNGNUSU6JRWK=
MOLT-16 MnXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXzRWlPUUN3ME20N{4xPSCwTR?= MULTRW5ITVJ?
23132-87 NVuwOI1YT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYD2SYJ[UUN3ME20N{4xPSCwTR?= MV\TRW5ITVJ?
PF-382 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\BTWM2OD12ND6yNkBvVQ>? MVPTRW5ITVJ?
ES3 MlfBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFX6[o5KSzVyPUS0MlYhdk1? M{LLeHNCVkeHUh?=
SW756 NXXncoNDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3nifmlEPTB;NEWuNVQhdk1? NIDVeWRUSU6JRWK=

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい
体内試験 Gemcitabine combined with C225 results in growth inhibition, tumor regression, and abrogation of metastasis in L3.6pl tumors established in the pancreas of nude mice. Gemcitabine treatment alone reduces median tumor volume from 538 to 152 mm3. Gemcitabine reduces the production of vascular endothelial growth factor and interleukin 8 in gemcitabine-treated tumors. [2] Gemcitabine is able to dramatically and specifically reduces the number of myeloid suppressor cells found in the spleens of animals bearing large tumors with no significant reductions in CD4(+) T cells, CD8(+) T cells, NK cells, macrophages, or B cells. [4] Gemcitabine combined with curcumin shows significant reductions in volume (P = 0.008 versus control; P = 0.036 versus gemcitabine alone), Ki-67 proliferation index (P = 0.030 versus control), NF-kappaB activation, and expression of NF-kappaB-regulated gene products (cyclin D1, c-myc, Bcl-2, Bcl-xL, cellular inhibitor of apoptosis protein-1, cyclooxygenase-2, matrix metalloproteinase, and vascular endothelial growth factor) compared with tumors from control mice treated with olive oil only. Gemcitabine combined with Curcumin is also highly effective in suppressing angiogenesis as indicated by a decrease in CD31(+) microvessel density. [5]

お薦めの試験操作（参考用のみ）

溶解度 (25°C)

体外 DMSO 52 mg/mL (197.56 mM)
Water 52 mg/mL warmed (197.56 mM)
Ethanol Insoluble
体内 左から（NMPから）右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
water (warmed)
混合させたのち直ちに使用することを推奨します。 		52mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 263.2
化学式

C9H11F2N3O4
CAS No. 95058-81-4
保管 粉
in solvent
別名 LY-188011, NSC 613327

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (g) = 濃度 (mol/L) x 体積 (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA（製品ページで利用可能な）。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます：

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます：C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA（オンラインで利用できる）で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください：

総分子量：g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03739619 Not yet recruiting Recurrent Hodgkin Lymphoma|Refractory Hodgkin Lymphoma|Classical Hodgkin Lymphoma|Hodgkin Lymphoma Emory University|Bristol-Myers Squibb November 1 2019 Phase 1|Phase 2
NCT03541486 Not yet recruiting Pancreatic Neoplasm Joseph J. Cullen|Holden Comprehensive Cancer Center|University of Iowa April 1 2019 Phase 2
NCT03417921 Not yet recruiting Pancreatic Cancer Ability Pharmaceuticals SL|The Cleveland Clinic April 1 2019 Phase 1|Phase 2
NCT03669601 Not yet recruiting Cancer CCTU- Cancer Theme|AstraZeneca|Cambridge University Hospitals NHS Foundation Trust March 31 2019 Phase 1
NCT03690739 Not yet recruiting Recurrent Ovarian Carcinoma AGO Research GmbH February 1 2019 Phase 3
NCT03085004 Not yet recruiting Pancreatic Cyst|EUS-FNA Milton S. Hershey Medical Center January 2019 Phase 3

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

よくある質問（FAQ）

  • 質問1：

    What is the difference between gemcitabine(S1714 ) and Gemcitabine HCl (S1149)?

  • 回答：

    Gemcitabine HCl is the HCl salt form of Gemcitabine. They have the same biological activities. The free base(S1714) dissolves better in DMSO, and the hydrochloride (S1149) dissolves better in water.

selleck catalog

DNA/RNA Synthesisシグナル伝達経路

相関DNA/RNA Synthesis製品

  • SCR7

    SCR7 is a specific DNA Ligase IV inhibitor, which blocks nonhomologous end-joining (NHEJ).

  • YK-4-279

    YK-4-279 is a potent inhibitor of EWS-FLI1 binding to RNA helicase A (RHA).

  • BMH-21

    BMH-21 is a DNA intercalator, which binds ribosomal DNA and inhibits RNA polymerase I (Pol I) transcription.

  • Cisplatin

    Cisplatin is an inorganic platinum complex, which is able to inhibit DNA synthesis by conforming DNA adducts in tumor cells.

    Features:One of the most widely used and most potent chemotherapeutic agents.

  • Gemcitabine HCl

    Gemcitabine HCl is a DNA synthesis inhibitor with IC50 of 50 nM, 40 nM, 18 nM and 12 nM in PANC1, MIAPaCa2, BxPC3 and Capan2 cells, respectively.

    Features:Gemcitabine has been used to treat pancreatic cancer and has demonstrated effective anti-tumor activity.

  • Bleomycin Sulfate

    Bleomycin Sulfate is a glycopeptide antibiotic and an anticancer agent for squamous cell carcinomas (SCC) with IC50 of 4 nM in UT-SCC-19A cells.

  • Fluorouracil (5-Fluoracil, 5-FU)

    Fluorouracil (5-Fluoracil, 5-FU) is a DNA/RNA synthesis inhibitor, which interrupts nucleotide synthetic by inhibiting thymidylate synthase (TS) in tumor cells.

Tags: Gemcitabine を買う | Gemcitabine ic50 | Gemcitabine 供給者 | Gemcitabine を購入する | Gemcitabine 費用 | Gemcitabine 生産者 | オーダーGemcitabine | Gemcitabine 化学構造 | Gemcitabine 分子量 | Gemcitabine 代理店
×

春節（旧正月）休暇に伴う納期遅延のお知らせ
上海工場が春節休業となるため、輸入が必要な製品の納期が通常より2週間ほど遅れます。
1月25日までにご注文いただきました製品は通常通り出荷させていただきます。1月28日-2月8日にご注文いただいた製品は２月19日以降の出荷となります。ご不便をおかけいたしますが、何卒ご理解くださいますようお願い申し上げます。

×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID